Light bulb in a gear icon, Therapeutics Grant

Therapeutics Grant

IDEA Therapeutics Grant - Accepting Applications in late Fall, 2022

Sponsored by the Office of Innovation and MUSC Foundation for Research Development, IDEA Therapeutics Grant provides $40,000 in Therapeutic-based product advancement to support short-term (six month) projects designed to improve the translation potential of an innovation by moving it to the next developmental milestone(s), thus increasing the likelihood of partnerships, licensing, or implementation.

Example milestones for the IDEA Therapeutics Grant include but are not limited to:

  • Medicinal chemistry to optimize compounds
  • Exploratory toxicology studies
  • Validation of a pharmacological target or translational biomarker
  • Efficacy studies
  • Assay development
  • Production

Innovations relying on development of digital or medical device technology are excluded from eligibility, as they are funded under the IDEA Technology Grant RFA.

This RFA is open to advance innovations protected by, or protectable by, IP that is assigned or assignable to MUSC pursuant the MUSC IP Policy. If a patent or patent application is not currently assigned to FRD, a Record of Invention or Disclosure of Copyrightable Work must be on file with FRD at least one month in advance of the application due date.

One project is anticipated to be funded this application cycle.


Applications for the current cycle were due November 1, 2021. Award notifications will be made on December 6, 2021.


The Application consists of five components:

  1. Each investigator's CV
  2. Project Summary, 1-page limit
  3. Budget and Justification: PHS 398format
  4. Project Proposal, 5-page limit
  5. Letter(s) of Support


Applications will be reviewed by a panel including scientific/technical evaluators, members from an external review board, Office of Innovation leadership, and FRD.

Review the Official RFA here.



The Office of Innovation